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Abstract

Introduction

Physico-chemical, metabolic and hormonal theories
regarding the pathogenesis of calcium oxalate nephrolithiasis do not sufficiently explain many features of this
disease. The recent findings of an abnormally faster
oxalate self-exchange and higher phosphorylation of
band 3 in erythrocytes of idiopathic calcium oxalate
stone formers suggest the hypothesis that nephrolithiasis
may be a cellular disease, characterized by a defect in
the function of the anion-exchange.
The cellular
anomaly seems genetically controlled. Band 3 anion
exchanger function seems to be biochemically regulated
through modulation of band 3 phosphorylation, which
depends on cyclic AMP- and phospholipid-sensitive
Ca2 + independent protein kinases. In this light, a
reduced glycosaminoglycan concentration in the
erythrocyte membranes of stone formers might play a
role, as these molecules exert a strong inhibitory effects
on band 3 phosphorylation and anion transport in vitro
and in vivo. An in vivo trial was performed in which
stone formers were administered glycosaminoglycans
orally. A reduction in oxalate excretion, and oxalate
renal clearance, and a simultaneous correction of the
abnormal RBC oxalate flux and band 3 phosphorylation
were observed. These data suggest the existence of a
link between the erythrocyte abnormality and oxalate
transport by the kidney and gut.

No less than 76 % of all kidney stones are made up
of calcium oxalate (CaOx), and in 80% of the cases we
are dealing with idiopathic forms of nephrolithiasis
(Nordin et al., 1979). The physico-chemical theory of
lithogenesis, explains stone formation by the precipitation, growth and crystalline aggregation of several lithogenic salts in the urine, and has contributed greatly to
the understanding of the complex problem of the etiology and pathogenesis of calcium urolithiasis (Fleisch,
1978). Calcium oxalate and calcium phosphate are potentially the most insoluble lithogenic salts under the
ionic conditions normally present in urine; indeed, their
supersaturation level even in the urine of non-stone
forming subjects is very close to the point of spontaneous precipitation.
The risk of forming CaOx stones is determined by
the degree of calcium salt supersaturation, and the activity level of factors stabilizing (inhibitors) and destabilizing (promoters) their nucleation, crystal-growth and
crystal-aggregation (Robertson et al., 1978). Idiopathic
calcium nephrolithiasis (ICN) is currently interpreted as
the consequence of an imbalance between these factors
(Robertson et al., 1978; Baggio et al., 1982).
The principal determinants of urine calcium salt saturation are urine pH, calcium and oxalate excretion, and
diuresis. Most studies addressed the role of calcium ion
in promoting ICN. In the last _decade, however, the
pathogenetic role of oxalate has been revaluated in the
light of physico-chemical considerations and clinical
findings (see for a review Smith, 1988). Indeed minimal changes in urinary oxalate concentration produced increase in CaOx supersaturation than equal variations in
calcium concentration (Finlayson, 1974). Moreover, severity of disease and entity of crystalluria were well correlated with oxaluria, rather than calciuria (Robertson
and Peacock, 1980).
While urine supersaturation clearly is necessary for
stone formation, it does not seem the sole prerequisite,
as urine supersaturation by the main lithogenic salts is
frequently present even in non-stone forming subjects
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(Robertson et al., 1968). These results led to the concept that there exist substances in urine that can inhibit
crystal nucleation, growth and aggregation; citrate, pyrophosphate, magnesium, glycoproteins and glycosaminoglycans (GAGs) seem endowed with such activity; in reference to GAGs, an inhibitory effect on CaOx crystal
growth in vitro was proven (Kok et al., 1988; Gjaldbaek
1982), and an excretion deficit in stone formers was
documented (Robertson et al., 1978; Baggio et al.,
1982; Caudarella et al., 1983; Martelli et al., 1985;
Baggio et al., 1987a; Nikkilii, 1989; Michelacci et al.,
1989), although not unanimously (Samuell, 1981; Hesse
et al., 1986; Fellstrom et al., 1986; Hwang et al.,
1988). Moreover in nephrolithiasis, not only a quantitative, but also a qualitative defect exists, because the
degree of GAG sulfation is higher than normal (Foye et
al., 1976; Fellstrom et al., 1986).
The causes that may lead to an imbalance between
saturation and urinary inhibition might reside in systemic, metabolic, or renal anomalies. The latter are certainly very important in the idiopathic forms of nephrolithiasis; in fact, primary tubular loss of calcium (Pak,
1979), reduced urinary citrate excretion due in part to
partial defect in renal acidification (Minisola et al.,
1989), and altered excretion of renal tubular epithelium
constituents, such as renal enzymes (Baggio et al.,
1983a), glycosaminoglycans, and Thamm-Horsfall glycoprotein (Gambaro et al., 1984) have been often reported. Several studies addressed whether the tubular anomalies were primitive and therefore pathogenetically important, or only a consequence of stone formation, but
no firm conclusion was reached (Jaeger et al., 1986);
nonetheless, there is evidence that at least some anomalies are primitive in nature.
From this brief digression, it appears evident that
ICN has been viewed above all as a physico-chemical
problem, or a metabolic and hormonal disorder. While
studies based on these approaches have been of great importance, several aspects are still unexplained, leading to
the recent concept that cellular anomalies might be determinant in ICN pathogenesis (Baggio et al., 1984a,
1986a).
In this review, we will discuss findings in support
of this theory, and their possible clinical and pharmacological applications.

vations buttressed this idea, in particular, the change in
the epidemiology and clinical pattern of urinary stone
disease (Robertson and Peacock, 1982), and the obvious
impact of environment, as seen in hypertension, in
which a possible primary cellular alteration is highly
suspected; moreover, further clinical and physico-chemical observations of the effect of even small increase in
urinary oxalate concentration on the lithogenetic process.

Alterations in Cellular Transport of Oxalate
The study of oxalate self-exchange through the
erythrocyte membrane under conditions of equilibrium
supported the working hypothesis. Anomalous transmembrane flux in red blood cells (RBC) was present in
70-80% of the subjects studied (Baggio et al., 1986a).
Other workers corroborated this finding (Jenkins et al.,
1988; Narula et al., 1988). As this disorder is not present in secondary forms of calcium nephrolithiasis, it
seems characteristic of ICN, and moreover, genetically
controlled, with a mendelian-type segregation. The simplest explanation is that the increased erythrocyte flux
has the features of an autosomal, monogenic dominant
trait with complete penetration, and variable expression.
However, a polygenic inheritance with frequent and
linked genes, and two different thresholds (one for
increased flux, and the other for nephrolithiasis) cannot
be ruled out.
In the families we studied, this anomaly was also
present in non stone-forming subjects. Moreover nephrolithiasis, which was detected only in subjects with
the anomaly, appeared more frequently in males, and
only after the second decade of life. These observations
further stressed the impact of environmental (diet, etc.)
and sex-linked factors.
We then tried to clarify the relationships between altered cellular oxalate flux and ICN; that is, whether we
were dealing with a pathogenetic or a casual association,
and if the anomaly could constitute a risk marker for
ICN. Follow-up studies in five families revealed five
new cases after five years of observation, and these occurred only in subjects with the cellular anomaly (unpublished). This finding suggested that this cellular trait
constitutes a risk marker of the disease.
The use of erythrocyte anion channel-inhibiting substances showed that the anomalous oxalate transport was
related to an alteration in band 3 cell protein function
(Baggio et al., 1984b). Proteins immunologically correlated with band 3 red cell protein were also detected in
the gut and kidney. Moreover, it was demonstrated that
band 3 renal protein in the basolateral membrane of intercalated alpha cells of the collecting duct is encoded by
the same gene that encodes band 3 erythrocyte protein
(Demuth et al., 1986; Brosius et al., 1989; Kudricki and

The Theory of Cellular Anomalies as the
Pathogenetic Factor
In developing a cellular hypothesis of this disease,
we considered that the co-existence of familial occurrence, tubular disease associated with ICN, and anomalies in the systemic handling of oxalate might suggest the
presence of a generalized cellular defect. Other obser-
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Shull, 1989). These cells are deputized to proton secretion (Steinmetz, 1986), and band 3 protein has a very
important role due to its anion transporting function,
particularly chloride and bicarbonate (Steinmetz, 1986).
On the basis of these biological considerations, we
investigated the presence of functional alterations in the
gut and kidney in subjects with the red cell anomaly.
We found that a more rapid intestinal oxalate absorption
(Baggio et al., 1986a) and abnormalities in distal acidification (Gambaro et al., 1988) were associated with increased erythrocytic flux. The former naturally may
translate into urinary oxalate excretory peaks, and hence
into peaks of urinary supersaturation for calcium oxalate; the latter have been repeatedly observed in ICN,
and are generally considered a consequence of the nephropathy (Jaeger et al., 1986), despite their possible
pathogenetic role in calcium-phosphate lithiasis, and definite causal role in overt type 1 renal tubular acidosis.
However, low distal tubular proton secretion, as seen in
this type of acidification defect, opposes our theory of a
hyperfunctioning anion carrier because, if the same RBC
defect is also present in alpha intercalated cells, proton
secretion would be favored, giving rise to more acidic
urine. However, studies in this sense in ICN patients
without acidification defects, showed that bicarbonate
infusion caused a significantly higher urine to blood
PCO 2 gradient in subjects with higher RBC oxalate selfexchange, compared to those with normal oxalate flux.
We reasoned that if the anion exchanger were hyperactive, it would have been more sensitive to peritubular bicarbonate concentration, one of the main factors controlling the activity of the basolateral anion exchanger of
alpha intercalated cells (Breyer et al., 1986). These two
apparently contradictory results are still puzzling us.
Although further study is mandatory, some very preliminary data suggest a redundant proton secretion, at least
by some CaOx stone formers. In these patients, the production of a more acidic urine after an acid load could
facilitate CaOx stone formation. In other words, therefore, not only an incomplete form of distal renal tubular
acidosis might exist in some stone formers, but also a
higher than normal proton excretion in another subset of
patients.

The hypothesis of a causal link between the two cellular abnormalities is suggestive, and supported by evidence that drugs, such as stilbenes, which bind covalently with the protein and inhibit its phosphorylation, in a
parallel manner also reduce cell transport of oxalate
(Baggio et al., 1984b), as well as the observation that
both anomalies seem dependent upon the intracellular energy level, as ATP depletion induces a reduction in both
oxalate flux and band 3 phosphorylation (Baggio et al.,
1986b). However, it is still debated whether anion
transport modulation involves phosphorylation of band
3, and other membrane proteins (Bursaux et al., 1984;
Clari et al., 1990; Yannoukakos et al., 1991). Preliminary results from our laboratory evidenced a close relationship between the level of band 3 phosphorylation and
its function as an anion exchanger. In fact, anion transport was unmodified by agents mediating cyclic AMP-,
or phospholipid-sensitive Ca2 + -dependent protein kinases that are responsible for phosphorylation of some
red cell membrane proteins, other than band 3 (Raval
and Allan, 1985). This is the case in adenylcyclase activation by forskolin, and in endogenous diacylglycerol increase following RBC incubation with phospholipase C
and Ca2 +, as well as the activation of protein kinase C
by phorbol myristate acetate or short incubation with
oleil-2-acetyl-rac-glycerol (OAG). On the other hand,
agents able to modify the phosphorylation state of the
erythrocyte anion carrier, such as low molecular weight
heparin or longer incubation with OAG, also induce
changes in oxalate transmembrane self-exchange. These
findings also suggest that cyclic AMP- and phospholipidsensitive Ca2 + -independent protein kinases are critical
modulators of band 3 function. Thus, our current views
on the possible mechanisms involved in the origin of the
erythrocytic anomalies associated with ICN suggest a
primary structural defect in band 3 protein might be
proposed, even though it is extremely unlikely that a
primitive defect involves simultaneously two proteins,
band 3 and 2 which are both abnormally phosphorylated
in stone formers (Baggio et al., 1986b). However, we
are addressing this aspect by evaluating the possible existence of a linkage between the increased RBC oxalate
flux and chromosome 17, where band 3 gene is located
(Lux et al., 1989). Our first attempt failed because the
large family we studied was not sufficiently informative
in reference to the probe employed.
The hypothesis of an imbalance between AMP- and
Ca2 + -insensitive protein kinases, and phosphatases
seems more interesting, and in this way it might be
more easily explained the link between RBC band 3
anomalies, and the oxalate carriers in the proximal tubule and in gut that have only structural and functional
homologies with band 3 protein, and are encoded by different genes (Alper et al., 1987). Despite their differ-

Alterations in the Red Blood Cell Anion Carrier
The biochemical basis of the anomalous erythrocyte
oxalate flux might reside in an altered phosphorylation
state of the membrane proteins, and in particular band 3,
which is the known anion carrier in red blood cells
(Cabantchik et al., 1978). Compared to controls, in
fact, phosphate incorporation is greater in the erythrocytic membranes of stone formers (Baggio et al., 1986b,
1987b).
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less, how they would influence the natural history of
nephrolithiasis is not known, as long-term prospective
studies are not yet available.
Drugs capable of favorably modifying the natural
history of the disease, such as hydrochlorothiazide
(Maschio et al., 1982), are undoubtedly able to correct
oxalate self-exchange in red blood cells (Baggio et al.,
1986a), and change band 3 protein phosphorylation kinetics (Baggio et al., 1987b). Other drugs, such as
amiloride (Baggio et al., 1987c; Clari et al., 1986) and
the calcium antagonists (Baggio et al., 1986c; Gambaro
et al., 1987) were able to normalize erythrocyte oxalate
flux, and the latter also induced a change in the urinary
excretion of calcium.
Glycosaminoglycans are also able to influence red
cell oxalate flux (Baggio et al., 1988; 199 la), and
probably exert this effect through their powerful modulating action on membrane kinases (Hathaway et al.,
1980; Lecomte and Boivin, 1981; Meggio et al., 1982;
Boivin et al., 1985), which are deputized to the phosphorylation of the anion carrier.
GIycosaminogl ycans are considered important inhibitors of lithogenesis; their urinary excretion is frequently
reduced in ICN patients; a decreased erythrocyte GAG
content has also been reported in ICN patients (Baggio
et al., 1990), and their synthesis in the fibroblasts of
stone-forming subjects seems reduced (Caudarella et al.,
1987). Since it is possible that an anomaly which is present in one cellular line might also be present in other
cell compartments, the pathogenetic role of glycosaminoglycans in ICN might be more complex than previously
thought.
In vitro, these drugs and in particular the low molecular weight heparins, heparan sulfate and dermatan
sulfate, albeit with different efficacy, are able to inhibit
band 3 protein phosphorylation, as well as red blood cell
oxalate flux at concentration of2.5 µglml (Baggio et al.,
1988), which is much lower than that needed to inhibit
protein kinase C (200 µg/1) (Wise et al., 1982). Our
findings are consistent with data from Hathaway et al.
(1980), Lecomte and Boivin (1981), and Clari and
Ferrari (1983) demonstrating that casein kinase is inhibited by heparin at concentrations of a few µg/1 or
ng/1, which are much lower than that needed for protein
kinase C. This was one more reason to exclude the protein kinase C-dependent pathway from the pathogenesis
of the cellular abnormality observed in nephrolithiasis.
To explore the possible clinical application of these
drngs in the prevention of stone relapses, and also to
obtain deeper insights into the pathogenesis of ICN, as
well as establish a definitive pathogenetic link between
the RBC oxalate anomaly and nephrolithiasis, we
searched for a link between the erythrocyte abnormality
and oxalate transport by the kidney and gut.

ences, these anion/oxalate carriers might depend upon
the same regulatory mechanisms, thus explaining parallel
derangements in their function. The putative imbalance
in kinase activities might involve both the enzymes
themselves, or modulating effectors of their activities.
This idea is supported by our finding of abnormally low
GAG level in erythrocytes from stone formers (Baggio
et al., 1990), as these molecules exert inhibitory effects
on band 3 phosphorylation and anion transport in vitro
and in vivo (see below) (Baggio et al., 1988, 1990,
1991a, 1991b).
Thus, the possibility exists that transport of other
ions also dependent upon the same mechanism would be
abnormal. Indeed, we recently observed a higher urate
self-exchange in ICN patients (Gambaro et al., 1990),
even though inconstantly associated with the faster oxalate transport, so raising the possibility that exchange is
specific for a certain ion, at least at some step of the
transport and/or its regulatory mechanism. Alternatively, a different hierarchy of affinity for carrier between
anions could explain these results.
Clinical and Pharmacological Considerations
That some cell alterations may be considered a possible primary metabolic defect in ICN opens new perspectives for defining the risk of nephrolithiasis, and
preventing recurrences pharmacologically. Concerning
the former, risk markers for nephrolithiasis are not yet
available at present. In fact, the anomalies associated
with this disease (hypercalciuria, hyperoxaluria, low
urinary citrate levels, defect in crystal agglomeration
inhibiting activity in urine, etc.) have been proposed as
risk markers only on the basis of case-control investigations between stone-formers and non-stone-formers,
without being tested in prospective studies to verify their
predictivity of the disease. On the other hand, based on
our family follow-up study (see above), increased red
blood cell oxalate flux might be a means to detect subjects at risk of ICN. This would make it possible to establish dietary or other types of regimes in these subjects, in order to prevent the disease from acting on
other non-genetic risk factors. However, as the impact
of environment on ICN and its possible relationship with
the cellular anomaly is not yet sufficiently understood,
further study is needed before this type of application
can be suggested.
In reference to pharmacologic prophylaxis, drugs
able to modulate the observed cellular abnormalities
could modify urinary physico-chemical conditions, and
hence the natural history of the disease. Several molecules have been studied in this sense, and fmdings were
favorable regarding cellular activity, and effect on urinary physico-chemical balance in many cases. Nonethe250
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Our rationale was that if we were able to correct the
RBC oxalate anomaly in vivo, oxalate transporters in the
kidney and in gut might respond similarly, leading to
changes in urinary excretion and clearance of oxalate,
since these carriers have molecular and functional similarities with erythrocyte band 3 (Alper et al., 1987).
GAGs seemed a good candidate to verify this hypothesis, as they are able to correct both oxalate self-exchange
and band 3 phosphorylation in erythrocytes.
For clinical use, oral administration is, of course,
preferable, but this route for GAGs is currently still considered unreliable; it is generally thought that they are
catabolized at the intestinal epithelial level to monosaccharides devoid of any pharmacological activity.
This is not true; Larsen et al. (1986) demonstrated the
presence of mainly oligo-, di- and mono-saccharides,
and to a minor extent octa-and tetra-saccharides in the
blood following a single oral dose of 35 S-heparin or 3Hheparin. At the same time an anti-factor Xa appeared,
probably due to the larger heparin fragments. These
workers also reported that oral administration of heparin
in the presence of cortisone induced a systemic antiangiogenic effect (Folkman et al., 1983). Norman et al.
(1985) found that the oral administration of a synthetic
GAG, sodium pentosan polysulphate, was followed by
a slight but significant increase in the negative zeta
potential in urine, a measure of the polyanionic inhibitory activity of crystallization. Intestinal absorption of
intact or large fragments of heparin and dermatan sulphate was recently demonstrated (Jaques et al., 1991,
Dawes et al., 1989).
We employed a mixture of GAGs extracted from
animals approved for human use in Italy, which is composed of two GAGs that are highly active in vitro on
RBC abnormalities (70% a heparin-like fraction, and
30% dermatan sulphate). Pharmacokinetic studies disclosed that almost 50 % of this drug is absorbed after
oral administration, and 25 % is excreted unmodified by
the kidney (unpublished). In view of these findings, we
may estimate that at least 15 mg/day of the drug are absorbed unaltered through the intestinal epithelium (daily
dose 60 mg time 25 %). If the distribution of this
heparinoid is in the vascular space alone (approximately
5 I), its plasma concentration would be about 3 mg/I
which, based on our in vitro data is certainly sufficient
to inhibit RBC oxalate flux up to 55 %, and RBC band
3 phosphorylation up to 30 %. Indeed, following oral
administration, this drug was effective on RBC anomalies (Baggio et al., 1991a) and at the same time exerted
a hypooxaluric action (Baggio et al., 1991b).
Although this drug, following intra-venous administration, was able to reduce renal oxalate clearance, its
hypooxaluric effect under steady-state conditions, such
as those of the 15 day trial, must also be necessarily due

to intestinal inhibition of dietary oxalate absorption
(Baggio et al., 1991b). As glycosaminoglycans do not
bind oxalate (Baggio et al., 1983b) we believe they act
at the intestinal level with a mechanism similar to that
most probably acting on the proximal tubular epithelium,
that is by modifying the phosphorylation of band 3-related transporters and, therefore, cellular oxalate flow. It
cannot be ruled out that the hypooxaluric effect may be
explained by a reduction in endogenous oxalate synthesis, or oxalate precipitation in the body of oxalate as a
calcium salt, but these hypotheses seem unlikely.
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Reviewer V: Have GAGs decreased stone formation in
patients with ICN?
Authors: To our knowledge there is only one open
clinical study in which the effect of GAGs on stone relapses was evaluated. Danielson et al. (1988) reported
that in 96 frequent relapsing stone forming patients
(some of whom had enteric disorders), pentosan polysulphate, 400 mg/daily, decreased the disease activity during a mean treatment time of 22 months. Pentosan polysulphate, a synthetic GAG, was orally administered at a
very high dosage capable of increasing the inhibition of
calcium oxalate crystal growth in urine. No effect was
observed on oxalate excretion. We have no experience
with this drug on RBC oxalate self-exchange, and unfortunately it is not possible to match this drug with the
animal extractive GAG used in our study due to their
different chemical structure, and to the different bioavailability (pentosan polysulphate has a very low oral
bioavailability, 0.5-1 %).

M. Akbarieh: The authors suggested that red blood cell
anomaly is a risk marker of ICN. How can the authors
explain this hypothesis, and how it might be tested?
Authors: When we published our family studies on the
genetics of the RBC anomaly in 1986, we observed that
not all the subjects presenting the anomaly had passed
stones (Baggio et al., 1986a). After a 5 year follow-up,
5 of those subjects became stone-formers. It is remarkable that only those with the RBC anomaly formed urinary stones; we believe that this is a clear demonstration
that abnormal oxalate self-exchange in erythrocytes is a
marker of the risk to become a stone-former.
Of
course, to strengthen this conviction, more families must
be studied with a longer follow-up, and more insights
into the physiopathological meaning of the cellular
anomaly in terms of nephrolithiasis must be gained.

Discussion with Reviewers

W. G. Robertson: If thiazides correct the oxalate transport excess in the red cells from stone formers, why do
they not reduce urinary oxalate excretion, since this
would be anticipated from the authors' model?
Authors: Our data show no relationship between 24
hour urinary oxalate and the flux rate constant of the
oxalate self-exchange in RBC. It seems that the difference between ICN patients with increased or normal
oxalate flux lies in a different time course of oxaluria
after oral challenge with oxalate. In fact, 8 hours after
challenge, oxalate recovery from the urine is the same
regardless of the presence or not of the RBC abnormality; however, subjects with increased RBC oxalate selfexchange displayed a faster excretion of oxalate in the
first 2-4 hours (Baggio et al., 1986a). It is true that
thiazides were never shown to reduce urinary oxalate excretion, but we wonder if they cannot modify the time
course of oxaluria after meals.

B. Hesse: To what extent did urinary oxalate excretion
decrease during treatment with GAGs, and was the decrease significantly correlated with reduced erythrocyte
oxalate self-exchange and band 3 protein phosphorylation?
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